LRMR

Larimar TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

The constructive case is still regulatory execution: Q2 2026 topline open-label data, Phase 3 screening planned for Q2 2026, first-patient dosing expected around mid-2026, and a June 2026 BLA target together create a visible catalyst stack into mid-2026 [#8-K-2026-03-19][#10-K-2026-03-19].

Posture

Defensive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta 0.0.

What can break

FDA could disagree with the accelerated-approval package, require more data, or determine the safety database is inadequate at BLA review.

Momentum

Value

Sentiment

100

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $5.20 · Bull $10.00 · Bear $2.20

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-29 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $16.60

Why

Momentum3 · Δ7d -4.3

Value41 · Δ7d +0.1

Sentiment100 · Δ7d 0.0

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Sentiment · See AI snapshot

Momentum

34% active weight

Current posture

7d trendFlat

Δ7d

-4.3

Δ21d

-10.9

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

100

33% active weight

Current posture

7d trendFlat

Δ7d

0.0

Δ21d

+18.2

Why this grade

Composite grade D. Momentum 2.8 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$364.63M

Beta

1.01

Shares Out

83.09M

P/E (TTM) · Derived

-3.3

P/S (TTM)

P/FCF (TTM) · Derived

-3.06

Rev YoY

EPS YoY

-150.8%

Gross Margin

Op Margin

Net Debt

-$183.45M

Current Ratio

4.06

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology